# US 2008/0306155 A1 · Method for treating renal disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306155 A1
- Document ID: US20080306155A1
- Status: Published application
- Kind: A1
- Application number: 12/141,585
- Filed: 2008-06-18
- Published: 2008-12-11
- Earliest claimed: 2004-09-16
- Inventors: Richard J. Roman; John R. Falck
- Web page: https://patentgrep.com/patent/US20080306155A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method preserving renal medullary blood flow in a renal disorder in a human or non-human animal is disclosed. The method involves administering 20-HETE or a 20-HETE analog to the human or non-human animal in an amount sufficient to attenuate a fall in renal medullary blood flow following a renal disorder. In addition, a method for preventing and treating ischemic acute renal failure is disclosed. The method involves administering 20-HETE or a 20-HETE agonist to the human or non-human animal in an amount sufficient to prevent or treat ischemic acute renal failure.

## Claims

### Claim 1

A method for preserving renal medullary blood flow caused by a renal disorder in a human or non-human animal comprising the step of:
administering an agent selected from the group consisting of 20-HETE and a 20-HETE analog to the human or non-human animal in an amount sufficient to prevent to treat the renal disorder.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method is for preserving medullary blood flow in a human subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the renal disorder is selected from the group consisting of proteinuria, diabetes-induced nephropathy, hypertension-induced nephropathy, kidney transplantation rejection, Heyman nephritis, remnant kidney nephropathy, ureteral obstruction nephropathy, a kidney disease caused by radiation, a kidney disease caused by an immunosuppressive drug, a kidney disease caused by a nephrotoxic drugs or toxins, renal ischemia-reperfusion injury and renal injury associate with shock.

### Claim 4 (depends on 1)

The method of claim 1, wherein the renal disorder is renal ischemia-reperfusion injury and renal injury associate with shock.

### Claim 5 (depends on 1)

The method of claim 1, wherein the agent is a 20-BETE analog.

### Claim 6 (depends on 5)

The method of claim 5, wherein the 20-HETE analog is defined by the formula:
wherein R1 is selected from the group consisting of carboxylic acid, phenol, amide, amine, imide, sulfonamide, sulfonamide, active methylene, 1,3-dicarbonyl, alcohol, thiol, tetrazole and other heteroaryl groups;
R2 is selected from the group consisting of carboxylic acid, phenol, amine, amide, imide, sulfonamide, sulfonamide, active methylene, 1,3-dicarbonyl, alcohol, thiol, tetrazole and other heteroaryl groups;
W is a carbon chain (C1 through C25) and may be linear, cyclic, or branched and may comprise heteroatoms;
Y is a carbon chain (C1 through C25) and may be linear, cyclic, or branched and may comprise heteroatoms;
sp<3 Center is selected from the group consisting of vinyl, aryl, heteroaryl, cyclopropyl, and acetylenic moieties;
X is an alkyl chain that may be linear, branched, cyclic or polycyclic and may comprise heteroatoms;
m is 0, 1, 2, 3, 4 or 5; and
n is 0, 1, 2, 3, 4 or 5.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound has a carboxyl or other ionizable group at either R1 or R2 and wherein the compound comprises a double bond or other functional group at a distance equal to 14-15 carbons from the ionizable group.

### Claim 8 (depends on 6)

The method of claim 6, wherein the compound comprises a length of 20-21 carbons, has a carboxyl or other ionizable group at either R1 or R2, comprises a double bond or other functional group at a distance equal to 14-15 carbons from the ionizable group, and comprises a hydroxyl group on the 20 or 21 carbon at either R1 or R2.

### Claim 9 (depends on 5)

The method of claim 5, wherein the 20-HETE analog is selected from the group consisting of 20-hydroxyeicosanoic acid, 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid (WIT003), N-methyl sulfonyl-20-hydroxyeicosa-5(Z),14(Z)-dienamide 5(Z),14(Z) 20-hydroxyeicosadienoic acid (5,14-20-HEDE) and N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine (5, 14-20-HEDGE).

### Claim 10 (depends on 9)

The method of claim 9, wherein the 20-HETE analog is N-[20-hydroxyeicosa-5(Z),14(Z)-dienoyl]glycine (5, 14-20-HEDGE).

### Claim 11 (depends on 1)

The method of claim 1 further comprising the step of:
observing an improvement in renal medullary blood flow in the human or non-human animal.

### Claim 12 (depends on 11)

The method of claim 11, wherein the improvement is an attenuation of a decrease in renal medullary blood flow brought about by the renal disease.

### Claim 13

A method for treating ischemic acute renal failure in a human or non-human animal comprising the step of:
administering a 20-HETE analog selected from the group consisting of N-methylsulfonyl-20-hydroxyeicosa-5(Z), 14(Z)-dienamide 5(Z), 14(Z) 20-hydroxyeicosadienoic acid (5,14-20-HEDE) and N-[20-hydroxyeicosa-5(Z), 14(Z)-dienoyl]glycine (5, 14-20-HEDGE) to the human or non-human animal in an amount sufficient to prevent or treat ischemic acute renal failure.

### Claim 14 (depends on 13)

The method of claim 13, wherein the method is for preventing or treating ischemic acute renal failure in a human.

### Claim 15 (depends on 13)

The method of claim 13 further comprising the step of monitoring the improving post-ischemia medullary blood flow of the kidney.
